Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 30

PMID 33920293

Citations 34

Authors

Allegra Ferrari

Isabelle Neefs

Sarah Hoeck

Marc Peeters

Guido Van Hal

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the leading cancer-related causes of death in the world. Since the 70s, many countries have adopted different CRC screening programs, which has resulted in a decrease in mortality. However, current screening test options still present downsides. The commercialized stool-based tests present high false-positive rates and low sensitivity, which negatively affects the detection of early stage carcinogenesis. The gold standard colonoscopy has low uptake due to its invasiveness and the perception of discomfort and embarrassment that the procedure may bring. In this review, we collected and described the latest data about alternative CRC screening techniques that can overcome these disadvantages. Web of Science and PubMed were employed as search engines for studies reporting on CRC screening tests and future perspectives. The searches generated 555 articles, of which 93 titles were selected. Finally, a total of 50 studies, describing 14 different CRC alternative tests, were included. Among the investigated techniques, the main feature that could have an impact on CRC screening perception and uptake was the ease of sample collection. Urine, exhaled breath, and blood-based tests promise to achieve good diagnostic performance (sensitivity of 63-100%, 90-95%, and 47-97%, respectively) while minimizing stress and discomfort for the patient.

Citing Articles

Clinical relevance of plasma-derived exosomal long non-coding RNAs (lncRNAs) CCAT1 and XIST in colorectal cancer patients.

Dana F, Mahjoub S, Shokati Eshkiki Z, Namazi A, Tabaeian S, Akbari A Mol Biol Res Commun. 2025; 14(2):157-166.

PMID: 40028475 PMC: 11865934. DOI: 10.22099/mbrc.2025.51654.2061.

DNA methylation analysis of the SDC2, SEPT9 and VIM genes in fecal DNA for colorectal cancer diagnosis.

Liu Y, Ming H, Xu L, Li L, Liu Q, Zhao J BMC Cancer. 2024; 24(1):1205.

PMID: 39350171 PMC: 11440654. DOI: 10.1186/s12885-024-12990-4.

Clinicopathological and molecular differences between stage IV screen-detected and interval colorectal cancers in the Flemish screening program.

Neefs I, Tran T, Ferrari A, Janssens S, Van Herck K, Op de Beeck K Front Oncol. 2024; 14:1409196.

PMID: 39286015 PMC: 11402608. DOI: 10.3389/fonc.2024.1409196.

Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection.

Maruzani R, Brierley L, Jorgensen A, Fowler A BMC Genomics. 2024; 25(1):827.

PMID: 39227777 PMC: 11370058. DOI: 10.1186/s12864-024-10737-w.

Utility of Stool-Based Tests for Colorectal Cancer Detection: A Comprehensive Review.

Gomez-Molina R, Suarez M, Martinez R, Chilet M, Bauca J, Mateo J Healthcare (Basel). 2024; 12(16).

PMID: 39201203 PMC: 11353969. DOI: 10.3390/healthcare12161645.

References

Nikolaou S, Qiu S, Fiorentino F, Rasheed S, Tekkis P, Kontovounisios C . Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol. 2018; 22(7):481-498. PMC: 6097737. DOI: 10.1007/s10151-018-1820-3. View

Zaccaro C, Saracino I, Fiorini G, Figura N, Holton J, Castelli V . Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT. Intern Emerg Med. 2017; 12(3):333-339. DOI: 10.1007/s11739-017-1610-3. View

Castellarin M, Warren R, Freeman J, Dreolini L, Krzywinski M, Strauss J . Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2011; 22(2):299-306. PMC: 3266037. DOI: 10.1101/gr.126516.111. View

Ng K, Anderson C, Marshall E, Minatel B, Enfield K, Saprunoff H . Piwi-interacting RNAs in cancer: emerging functions and clinical utility. Mol Cancer. 2016; 15:5. PMC: 4714483. DOI: 10.1186/s12943-016-0491-9. View

Che Alhadi S, Wan Zain W, Zahari Z, Md Hashim M, Syed Abd Aziz S, Zakaria Z . The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative Study. Ann Coloproctol. 2020; 36(6):409-414. PMC: 7837393. DOI: 10.3393/ac.2020.08.27. View

van Keulen K, Jansen M, Schrauwen R, Kolkman J, Siersema P . Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer. Aliment Pharmacol Ther. 2019; 51(3):334-346. PMC: 7003780. DOI: 10.1111/apt.15622. View

Bond A, Greenwood R, Lewis S, Corfe B, Sarkar S, OToole P . Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. Aliment Pharmacol Ther. 2019; 49(8):1005-1012. PMC: 6593415. DOI: 10.1111/apt.15140. View

Chandrapalan S, Arasaradnam R . Urine as a biological modality for colorectal cancer detection. Expert Rev Mol Diagn. 2020; 20(5):489-496. DOI: 10.1080/14737159.2020.1738928. View

Bhardwaj M, Weigl K, Tikk K, Benner A, Schrotz-King P, Brenner H . Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. Mol Oncol. 2019; 14(1):8-21. PMC: 6944100. DOI: 10.1002/1878-0261.12591. View

10.

Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z . Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015; 6:6528. DOI: 10.1038/ncomms7528. View

11.

Widlak M, Neal M, Daulton E, Thomas C, Tomkins C, Singh B . Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers. Colorectal Dis. 2018; 20(12):O335-O342. DOI: 10.1111/codi.14431. View

12.

Tost J . Current and Emerging Technologies for the Analysis of the Genome-Wide and Locus-Specific DNA Methylation Patterns. Adv Exp Med Biol. 2016; 945:343-430. DOI: 10.1007/978-3-319-43624-1_15. View

13.

Ishibe A, Ota M, Takeshita A, Tsuboi H, Kizuka S, Oka H . Detection of gas components as a novel diagnostic method for colorectal cancer. Ann Gastroenterol Surg. 2018; 2(2):147-153. PMC: 5881347. DOI: 10.1002/ags3.12056. View

14.

Alves Martins B, de Bulhoes G, Cavalcanti I, Martins M, de Oliveira P, Martins A . Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research. Front Oncol. 2019; 9:1284. PMC: 6890575. DOI: 10.3389/fonc.2019.01284. View

15.

Clarke G, Stilling R, Kennedy P, Stanton C, Cryan J, Dinan T . Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014; 28(8):1221-38. PMC: 5414803. DOI: 10.1210/me.2014-1108. View

16.

de Lacy Costello B, Amann A, Al-Kateb H, Flynn C, Filipiak W, Khalid T . A review of the volatiles from the healthy human body. J Breath Res. 2014; 8(1):014001. DOI: 10.1088/1752-7155/8/1/014001. View

17.

Boonsongserm P, Angsuwatcharakon P, Puttipanyalears C, Aporntewan C, Kongruttanachok N, Aksornkitti V . Tumor-induced DNA methylation in the white blood cells of patients with colorectal cancer. Oncol Lett. 2019; 18(3):3039-3048. PMC: 6676401. DOI: 10.3892/ol.2019.10638. View

18.

Song E, Byeon J, Lee S, Yoo H, Kim S, Lee S . Fecal Fatty Acid Profiling as a Potential New Screening Biomarker in Patients with Colorectal Cancer. Dig Dis Sci. 2018; 63(5):1229-1236. DOI: 10.1007/s10620-018-4982-y. View

19.

De Rubis G, Rajeev Krishnan S, Bebawy M . Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci. 2019; 40(3):172-186. DOI: 10.1016/j.tips.2019.01.006. View

20.

Pakiet A, Kobiela J, Stepnowski P, Sledzinski T, Mika A . Changes in lipids composition and metabolism in colorectal cancer: a review. Lipids Health Dis. 2019; 18(1):29. PMC: 6347819. DOI: 10.1186/s12944-019-0977-8. View